RT Journal Article
SR Electronic
T1 CTGF is a Modifiable Mediator of Flow-dependent Atherosclerosis under Peripheral Artery Disease Conditions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.25.23289120
DO 10.1101/2023.04.25.23289120
A1 Feifei Li
A1 Sandeep Kumar
A1 Anastassia Pokutta-Paskaleva
A1 Victor Omojola
A1 Dong-won Kang
A1 Chanwoo Kim
A1 Julia Raykin
A1 Carson Hoffmann
A1 Maiko Teichmann
A1 Jing Ma
A1 Hiromi Yanigasawa
A1 Andrew Leask
A1 Lucas Timmins
A1 Xiangqin Cui
A1 Roy Sutliff
A1 Rudy L. Gleason, Jr.
A1 Hanjoong Jo
A1 Luke Brewster
YR 2023
UL http://medrxiv.org/content/early/2023/05/04/2023.04.25.23289120.abstract
AB Background Peripheral arterial disease (PAD) is the 3rd leading type of atherosclerotic disease (ASD) morbidity. Arterial stiffness is intimately connected to the onset and progression of peripheral artery disease (PAD). The role of arterial stiffening on flow-mediated atherosclerotic plaque formation is not well understood. The objective of this study is to discover endothelial cell (EC) pathways under PAD conditions and test the modifiability of these pathways on ASD.Methods PAD conditions in mice were conferred by partial carotid ligation to induce disturbed Flow (D-flow) in pre-stiffened Fibulin-5 knockout (KO) mice that lack normal elastin function. EC pathways, including Connective tissue growth factor (CTGF/CCN) were quantified by gene analysis and histology. Atherogenic mice had PCSK9 infection + high fat diet. CTGF was inhibited in an EC-specific knockout (ECKOCTGF) and with a CTGF antibody (FG-3149). Human vascular tissue was used to validate PAD biomechanics and CTGF upregulation.Results Biomechanical testing demonstrated that d-flow KO arteries mimic biomechanics of PAD arteries. RNA microarray, qPCR, and immunohistochemistry identified EC plasticity in these arteries compared to WT and KO under stable flow. Under atherogenic conditions, KO arteries demonstrated vulnerable plaques not seen in WT animals. CTGF expression was increased by d-flow, in KO arteries, in aged (18 months) WT arteries, and vascular tissue under d-flow. CTGF inhibition by ECKOCTGF favorably improved plaque characteristics in male but not female animals. FG-3149 treatment of ECWTCTGF male animals delivered similar benefits to plaque characteristics and arterial compliance.Conclusion ECs in PAD arteries exist under a complex hemodynamic environment that integrates stiffness and d-flow into an atherogenic and inflammatory environment. Stiffness + d-flow stimulates precocious onset of EC plasticity and a vulnerable plaque phenotype. CTGF is a matricellular protein that can tune fibro-inflammatory pathways. CTGF is a prominent mediator of D-flow-mediated arterial remodeling and focal atherosclerotic plaque remodeling. Inhibition of CTGF improves plaque phenotype and arterial compliance. CTGF-associated pathways hold promise as therapeutic targets for PAD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by awards from the National Institutes of Health to Drs. Brewster, Gleason, and Jo (HL143348). The authors' work is supported by funding from the NIH grants HL119798, HL139757, and HL151358 (to H.J.). H.J. was also supported by Wallace H. Coulter Distinguished Faculty Professorship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory University approved IRB protocol numbers: 51432 and 70813I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableResource Availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Lead Contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Luke Brewster. Materials Availability Further requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Luke Brewster. This study did not generate new unique reagents. Data availability The RNA files generated from the study (fibulin-5 KO and WT animals) will be available at the NCBI GEO repository on January 1, 2024, as GEO Submission (accession number GSE222583). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE222583